Repaglinide

• Catalog No.: R9028
• CAS Number: 135062-02-1
• M. F.: C27H36N2O4
• M. W.: 452.58574
• Purity: ≥98% (HPLC)

SYNONYMS

• IUPAC name: 2-ethoxy-4-({[(1S)-3-methyl-1-[2-(piperidin-1-yl)phenyl]butyl]carbamoyl}methyl)benzoic acid
• IUPAC Traditional name: repaglinide
• Synonyms: NovoNorm; (S)-(+)-2-Ethoxy-4-[N-[1-(2-piperidinophenyl)-3-methyl-1-butyl]aminocarbonylmethyl]benzoic acid; Prandin

DATABASE IDS

• MDL Number: MFCD00906179
• CAS Number: 135062-02-1
• PubChem SID: 24724596

PROPERTIES

• Empirical Formula (Hill Notation): C27H36N2O4
• Purity: ≥98% (HPLC)
• Gene Information: human ... KCNJ1(3758)
• Apperance: white solid
• Melting Point: 129-130.2 °C
• Solubility: DMSO: >20 mg/mL
• Personal Protective Equipment: Eyeshields, Gloves, type N95 (US), type P1 (EN143) respirator filter
• RTECS: DI0876305
• Storage Temperature: 2-8°C
• German water hazard class: 2

DETAILS

Description (English)

Biochem/physiol Actions
Repaglinide is a potent short-acting insulin secretagogue that acts by closing ATP-sensitive potassium (KATP) channels in the plasma membrane of the pancreatic beta cell. It represents a new class of insulin secretagogues, structurally unrelated to sulphonylureas, which were developed for the treatment of type 2 diabetes.

Description (简体中文)

Biochem/physiol Actions
Repaglinide is a potent short-acting insulin secretagogue that acts by closing ATP-sensitive potassium (KATP) channels in the plasma membrane of the pancreatic beta cell. It represents a new class of insulin secretagogues, structurally unrelated to sulphonylureas, which were developed for the treatment of type 2 diabetes.